MedPath

Caffeine

Generic Name
Caffeine
Brand Names
Anacin, Arthriten Inflammatory Pain, Ascomp, Bc Arthritis, Bc Original Formula, Cafcit, Diurex, Dvorah, Esgic, Exaprin, Excedrin, Excedrin Tension Headache, Fioricet, Fioricet With Codeine, Fiorinal, Goody's Extra Strength, Goody's Headache Relief Shot, Goody's PM, Midol Complete, Midol Cramps & Bodyaches, Migergot, Norgesic, Norgesic Forte, Orbivan, Orphengesic, Pamprin Max Formula, Peyona, Stanback Headache Powder Reformulated Jan 2011, Trezix, Trianal, Trianal C, Triatec, Triatec-8, Vanatol, Vanatol S, Vanquish, Vivarin, Peyona (previously Nymusa), Gencebok
Drug Type
Small Molecule
Chemical Formula
C8H10N4O2
CAS Number
58-08-2
Unique Ingredient Identifier
3G6A5W338E
Background

Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to Theophylline and Theobromine. It can be sourced from coffee beans, but also occurs naturally in various teas and cacao beans, which are different than coffee beans. Caffeine is also used in a variety of cosmetic products and can be administered topically, orally, by inhalation, or by injection.

The caffeine citrate injection, used for apnea of the premature newborn, was initially approved by the FDA in 1999. According to an article from 2017, more than 15 million babies are born prematurely worldwide. This correlates to about 1 in 10 births. Premature birth can lead to apnea and bronchopulmonary dysplasia, a condition that interferes with lung development and may eventually cause asthma or early onset emphysema in those born prematurely. Caffeine is beneficial in preventing and treating apnea and bronchopulmonary dysplasia in newborns, improving the quality of life of premature infants.

Indication

Caffeine is indicated for the short term treatment of apnea of prematurity in infants and off label for the prevention and treatment of bronchopulmonary dysplasia caused by premature birth. In addition, it is indicated in combination with sodium benzoate to treat respiratory depression resulting from an overdose with CNS depressant drugs. Caffeine has a broad range of over the counter uses, and is found in energy supplements, athletic enhancement products, pain relief products, as well as cosmetic products.

Associated Conditions
Acute Pain, Chronic Lung Disease of Prematurity, Common Cold, Dyspepsia, Fatigue, Fever, Flu caused by Influenza, Headache, Menstrual Pain, Myalgia, Pain, Pain caused by Rheumatism, Primary apnea of premature newborns, Respiratory Depression, Somnolence, Tension Headache, Toothache, Under-eyes Dark Circles, Vascular Headaches, Moderate Pain
Associated Therapies
Analgesia, Antacid therapy, Athletic Performance

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

Phase 1
Completed
Conditions
Solid Tumors
Interventions
First Posted Date
2012-01-25
Last Posted Date
2019-02-12
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
28
Registration Number
NCT01517399
Locations
🇺🇸

START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States

Effects of Caffeine in Hydration and Energy Metabolism

Not Applicable
Completed
Conditions
Caffeine
Interventions
Drug: Placebo
First Posted Date
2011-11-22
Last Posted Date
2011-11-22
Lead Sponsor
Technical University of Lisbon
Target Recruit Count
30
Registration Number
NCT01477294
Locations
🇵🇹

Faculty of Human Kinetics, Lisbon, Portugal

Caffeine Citrate for the Treatment of Apnea Associated With Bronchiolitis in Young Infants

Not Applicable
Completed
Conditions
Apnea
Caffeine
Bronchiolitis
Interventions
Drug: Normal saline
First Posted Date
2011-09-16
Last Posted Date
2015-04-01
Lead Sponsor
Hamad Medical Corporation
Target Recruit Count
90
Registration Number
NCT01435486
Locations
🇶🇦

Pediatric emergency center, Hamad Medical Corporation, Doha, Qatar

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Phase 4
Completed
Conditions
Gastrointestinal Stroma Tumor
Non Small-cell Lung Cancer
Renal-cell Cancer
First Posted Date
2011-07-26
Last Posted Date
2016-02-02
Lead Sponsor
Markus Joerger
Target Recruit Count
54
Registration Number
NCT01402089
Locations
🇨🇭

Cantonal Hospital St.Gallen, St.Gallen, Switzerland

Caffeine in Children With Obstructive Sleep Apnea, Dose Response Study

Not Applicable
Terminated
Conditions
Obstructive Sleep Apnea
Enlargement of Tonsil or Adenoid
Interventions
First Posted Date
2011-05-06
Last Posted Date
2016-05-13
Lead Sponsor
The University of Texas Health Science Center, Houston
Target Recruit Count
42
Registration Number
NCT01349205
Locations
🇺🇸

Memorial Hermann Hospital, Houston, Texas, United States

A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)

Phase 1
Completed
Conditions
Infectious Disease
Interventions
First Posted Date
2011-01-12
Last Posted Date
2020-06-11
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
49
Registration Number
NCT01275170

Caffeine for Motor Manifestations of Parkinson's Disease

Phase 2
Completed
Conditions
Parkinson's Disease
Interventions
First Posted Date
2010-08-30
Last Posted Date
2015-04-16
Lead Sponsor
Ron Postuma
Target Recruit Count
28
Registration Number
NCT01190735
Locations
🇨🇦

Montreal General Hospital, Montreal, Quebec, Canada

The Effect of Caffeine in Elderly Citizen Following Eight Hour Abstinence From Caffeine Containing Drinks & Foods

Phase 4
Completed
Conditions
Healthy
Elderly
Interventions
First Posted Date
2010-01-13
Last Posted Date
2010-01-13
Lead Sponsor
Herning Hospital
Target Recruit Count
30
Registration Number
NCT01048515
Locations
🇩🇰

Surgical Research Department, Herning, Midtjylland, Denmark

Caffeine for Apnea of Prematurity-Sleep (CAP-S) Study

Phase 3
Completed
Conditions
Apnea of Prematurity
Interventions
First Posted Date
2009-11-25
Last Posted Date
2014-12-05
Lead Sponsor
McMaster University
Target Recruit Count
201
Registration Number
NCT01020357
Locations
🇨🇦

McMaster University Medical Centre, Hamilton, Ontario, Canada

🇦🇺

Mercy Hospital for Women, Melbourne, Australia

🇦🇺

Royal Women's Hospital, Melbourne, Australia

and more 1 locations

Development of Cocktail for Measuring the Activity of Important Cytochrome P450 Enzymes

Not Applicable
Terminated
Conditions
Cytochrome P450 Phenotype and Genotype Metrics
Interventions
Drug: Tramadol, omeprazole, losartan, caffeine
First Posted Date
2009-09-22
Last Posted Date
2010-06-28
Lead Sponsor
University of Southern Denmark
Target Recruit Count
412
Registration Number
NCT00981929
Locations
🇩🇰

University of Southern Denmark, Clinical Pharmacology, Odense, Fyn, Denmark

© Copyright 2025. All Rights Reserved by MedPath